JUNIOR STRENGTH MOTRIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JUNIOR STRENGTH MOTRIN (JUNIOR STRENGTH MOTRIN).
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
| Metabolism | Primarily hepatic via CYP2C9, with minor contributions from CYP2C8 and glucuronidation. |
| Excretion | Renal excretion of inactive metabolites and conjugates (>90%); less than 10% excreted unchanged. Fecal elimination minor (<5%). |
| Half-life | 1.5-2 hours in children; prolonged in neonates (up to 30 hours) and renal impairment. Clinical: short half-life requires frequent dosing for sustained antipyresis/analgesia. |
| Protein binding | 99% bound to albumin. |
| Volume of Distribution | 0.2 L/kg in children; low Vd indicates limited tissue distribution and high plasma protein binding. Clinical: mainly confined to vascular compartment. |
| Bioavailability | Oral: 80-100% (rapid absorption); rectal: approximately 70-80%. |
| Onset of Action | Oral: 30-60 minutes for antipyresis; 1-2 hours for analgesia. |
| Duration of Action | 4-6 hours for fever reduction; 6-8 hours for pain relief. Duration shorter than adults due to faster clearance. |
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | GFR 30-59 mL/min: reduce dose by 50% or avoid; GFR <30 mL/min: contraindicated. |
| Liver impairment | Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use. |
| Pediatric use | 6 months to 12 years: 5-10 mg/kg per dose orally every 6-8 hours; maximum 40 mg/kg/day. |
| Geriatric use | Initiate at lowest effective dose; consider renal function; increase dosing interval to every 6-8 hours. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for JUNIOR STRENGTH MOTRIN (JUNIOR STRENGTH MOTRIN).
| Breastfeeding | Ibuprofen is excreted into breast milk in very low amounts (M/P ratio approximately 0.01-0.02). Peak milk concentration occurs 1-2 hours after maternal dose. Due to the low concentration and short half-life in infants, ibuprofen is considered compatible with breastfeeding when used at recommended doses for short durations. |
| Teratogenic Risk | First trimester: Increased risk of miscarriage and congenital malformations (cardiac, gastroschisis) with NSAID use; a causal relationship has not been firmly established. Second trimester: Generally considered lower risk, but avoid prolonged use. Third trimester: Known association with premature closure of the ductus arteriosus, oligohydramnios, and fetal renal dysfunction; contraindicated after 30 weeks gestation. |
■ FDA Black Box Warning
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
| Common Effects | Stomach pain Nausea Diarrhea |
| Serious Effects |
Hypersensitivity to ibuprofen or any NSAID; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; severe renal impairment; history of GI bleeding or perforation related to NSAIDs.
| Precautions | Risk of GI ulceration, bleeding, and perforation; increased cardiovascular thrombotic events; hypertension; fluid retention and edema; severe skin reactions (e.g., Stevens-Johnson syndrome); renal toxicity, especially in patients with impaired renal function; anaphylactoid reactions. |
Loading safety data…
| Fetal Monitoring | Monitor maternal renal function, blood pressure, and signs of gastrointestinal bleeding. For prolonged use or use after 20 weeks gestation, fetal ultrasound to assess amniotic fluid volume and ductus arteriosus patency. Consider fetal echocardiography if used near term. |
| Fertility Effects | Ibuprofen may impair female fertility by interfering with ovulation through inhibition of prostaglandin synthesis. Effects are reversible upon discontinuation. No known adverse effects on male fertility. |